

BIOSECURE ACT: *What They're Saying*

The following statements and analyses are from notable industry experts and commentators on WuXi AppTec's role in the biopharmaceutical industry and the potential impact of the BIOSECURE Act.

DAMAGING IMPACT OF THE BIOSECURE ACT

As published in a study by GlobalData, [BIOSECURE Act could impact US biopharma drugs, with half in clinical trials, reveals GlobalData](#):

- *“Several biopharmaceutical companies, including Merck, Gilead Sciences, and Vertex Pharmaceuticals, have **cited increased costs, delays in clinical trials, US Food and Drug Administration (FDA) regulatory submissions and launch of drugs as potential impacts of the BIOSECURE Act.**”*

As read in The Economist, [America's moves against Chinese biotech will hurt patients at home](#):

- *“The muddier the motivation behind the legislation seems, the harder it is to escape the conclusion that old-fashioned protectionism is at play. And that is a problem, because it means **the bill would unduly hurt American consumers, without delivering any of the supposed security benefits.**”*
- *“If the legislation passes, as seems likely, **drug shortages and delayed clinical trials for medicines would probably follow.** ... And **that would go against another stated intention of the Biden administration: to lower drug prices.**”*

As read in The Economist, [America hits Chinese biotech—and its own drugmakers](#):

- *“For biotech startups, which tend to rely on Chinese partners with proven records to save time and money on research and manufacturing, **the biosecure bill could be an existential threat.**”*

[Bob Nelsen, Co-Founder and Managing Director, Arch Ventures](#) on the negative impact of banning WuXi AppTec from the U.S. market:

- *“Nelsen warned of **serious unintended negative consequences for U.S. competitiveness if Chinese contract manufacturing and development organizations WuXi AppTec Co. Ltd. and WuXi Biologics Inc. are banned from the U.S.** Rather than banning Chinese CDMOs, ‘we should be encouraging U.S. manufacturing, we should be encouraging the reimagining of manufacturing in biology to make it more efficient and more effective. There’s an opportunity for the U.S. to win in that.’”*

[Peter Kolchinsky, PhD, Managing Partner, RA Capital Management and Tess Cameron, Principal of Strategic Finance, RA Capital Management](#) on the impact of US Government targeting of WuXi AppTec:

- *“**To abruptly move on from WuXi, US biotech companies would likely incur delays of at least a year or two and (more in some cases).** Furthermore, the cost of purchasing WuXi’s services elsewhere would likely be 25% higher. **Ultimately, we’d be delaying access to important new medicines and maybe even shuttering some projects unless we believed that the US would bear higher drug prices to justify the higher costs of R&D.**”*

[Brian Safina, President and CSO, Magnet Biomedicine](#) on the impact of targeting WuXi AppTec:

- *“**...a WuXi crackdown could be ‘incredibly disruptive’ for companies that are nearing clinical testing.** ‘That could just completely destroy a biotech...’”*

[BIO Chairman Ted Love](#) speaking at BIO CEO & Investor Conference on the collateral dangers of targeting WuXi AppTec:

- *“Love cited WuXi, one of the companies targeted, claiming that **damaging the company would have a negative impact on patients, investors, and workers at the companies US-based facilities.** ‘People are jumping on the anti-China rhetoric and get going on that and are not careful about possible outcomes.’”*

WUXI APTEC’S ROLE AS AN IMPORTANT INDUSTRY PARTNER

[Richard Mason, CEO, Apollo Therapeutics](#) on working with WuXi AppTec:

- *“The thing that has pleasantly surprised me ... is the **consist excellence in the service they provide.** I guess there might be instances in the past where some companies in China might not be operating at the right standard. Our evidence is that is not true – **they are very, very good. That is a fact, they’re good.**”*
- *“We take our intellectual property extremely seriously and we don’t perceive any risks in working with these couple of companies in that respect. It’s hard to see how it would happen, anyway.”*

[Louis Garguilo, Chief Editor, Outsourced Pharma](#) on WuXi AppTec’s contributions to the U.S. biotech industry:

- *“WuXi’s global facilities greatly assist the U.S. biotechnology industry, have aided in reshoring of U.S. manufacturing, and served U.S. communities well. Like all CDMOs, the WuXi business model is predicated on advancing science and technology, and producing materials and drugs for sponsors and patients.”*

[Jonathan Kil, CEO, Sound Pharmaceuticals](#) on his company’s [partnership](#) with WuXi AppTec:

- *“In terms of timing and quality, it’s hard to beat WuXi,’ Sound CEO Jonathan Kil told Endpoints. Switching providers could mean a two-year delay, he estimates.”*
- *“It would be terrible for anyone to restrict our ability to work with WuXi AppTec.”*

[Harvey J. Berger, MD, Chairman and CEO, Kojin Therapeutics](#) on the positive impactful role that WuXi AppTec plays in the US biotech industry:

- *“Ensuring that @WuXi_AppTec remains a strong partner in our #biotech and #drugdiscovery ecosystem is essential to the vibrancy of our industry. They help make our drug discovery cost-effective & competitive & are needed to ensure continued investment in our businesses.”*

[Brian Fiske, Founder, Mythic Therapeutics](#) on WuXi AppTec’s impactful role in the biotech industry:

- *“Oh wait, Ginko can't compete so let's ban their competition? Not good for patients. **WuXi have always been amazing partners to get important drugs to patients faster.**”*